QURE

QURE is effectively a single-asset bet on AMT-130 for Huntington's disease, and the central pillar of that bet cracked between December 2025 and March 2026. After September 2025 'positive topline' data, the FDA's pre-BLA and Type A meeting minutes concluded that the Phase I/II data versus an Enroll-HD external control 'cannot' provide the primary evidence of effectiveness, and 'strongly recommended' a prospective, randomized, double-blind, sham-surgery-controlled study. That is the difference between a near-term filing and a multi-year, capital-intensive new trial — a textbook re-rating event that the current price has not digested. Breakthrough/RMAT/Orphan/Fast Track designations do not substitute for the controlled efficacy data the agency now demands.

The valuation cannot absorb that setback. Market cap is $2.96B against FY2025 revenue of just $16.1M (P/S 184x), and revenue is not a business line — it is collapsing collaboration/grant income, down 40.6% YoY and down from $524M in FY2021. The company posted a -$199M net loss, -$185M operating loss (-1,151% operating margin), and burned $178M of operating cash. There is no fundamental floor under the price; it is pure pipeline optionality, and the option just moved out of the money on timeline and probability.